Similarly, V-Raf murine sarcoma viral oncogene homolog B (BRAF) gene mutations, detected in few cases of NSCLC patients, have emerged as predictive biomarkers in the clinical stratification of NSCLC patients who show clinical sensitivity to TKI treatments, particularly, vemurafenib and dabrafenib plus trametinib [10,11]. Here, BRAF is linked to non-small cell lung carcinoma.